An Open-Label, Multicenter, Monotherapy, Dose-Escalation, Phase 1 Clinical Trial of NB02 (Posseltinib) in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma
This trial is an open-label, multicenter, monotherapy, dose-escalation, phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of NB02 (posseltinib) in patients with relapsed/refractory NHL including FL, MCL and MZL
• Age 19 to 80 years.
• Patients must voluntarily agree to participate in the study and provide written informed consent prior to any study-related procedures.
• Patients with histologically confirmed follicular lymphoma, mantle cell lymphoma or marginal zone lymphoma.
• relapsed/refractory Patients who have received more than two prior lines of therapy.
• Measurable disease based on Lugano classification.
• Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
• Adequate organ function including: